Novartis shares slide after heart drug fails late-stage trial target
Novartis said its experimental medicine failed to reduce cardiovascular risk in a late-stage trial, sending shares down 3.2% in European morning trading Monday.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.